TY  - JOUR
AU  - Taxonera, Carlos
AU  - Rodríguez, Cristina
AU  - Bertoletti, Federico
AU  - Menchén, Luís
AU  - Arribas, Julia
AU  - Sierra, Mónica
AU  - Arias, Lara
AU  - Martínez-Montiel, Pilar
AU  - Juan, Alba
AU  - Iglesias, Eva
AU  - Algaba, Alicia
AU  - Manceñido, Noemí
AU  - Rivero, Montserrat
AU  - Barreiro-de Acosta, Manuel
AU  - López-Serrano, Pilar
AU  - Argüelles-Arias, Federico
AU  - Gutierrez, Ana
AU  - Busquets, David
AU  - Gisbert, Javier P
AU  - Olivares, David
AU  - Calvo, Marta
AU  - Alba, Cristina
AU  - Collaborators
PY  - 2017
DO  - 10.1097/MIB.0000000000001144
UR  - http://hdl.handle.net/10668/11368
T2  - Inflammatory bowel diseases
AB  - Golimumab efficacy data in ulcerative colitis (UC) are limited to anti-tumor necrosis factor α (TNF)-naive patients. The aim of this study was to assess the short-term and long-term efficacy of golimumab used as first, second, or third anti-TNF in UC...
LA  - en
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - Colitis, Ulcerative
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Prognosis
KW  - Remission Induction
KW  - Retrospective Studies
KW  - Severity of Illness Index
KW  - Survival Rate
KW  - Tumor Necrosis Factor-alpha
KW  - Young Adult
TI  - Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
TY  - research article
VL  - 23
ER  -